Certain Lung Cancer Biomarkers Slip Through DNA-Only Testing, Study Warns

Lung cancer remains one of the most genomically complex malignancies clinicians encounter, and a new study is adding fresh urgency to a debate that has been quietly building in oncology genomics circles: DNA sequencing alone may not be enough. Research published this week indicates that certain clinically relevant lung cancer biomarkers can evade detection when laboratories rely exclusively on DNA-based testing platforms, a finding with direct implications for treatment selection and patient outcomes.

The Technology Gap at the Center of the Debate

The core issue centers on the biological diversity of actionable alterations in non-small cell lung cancer. While DNA sequencing has become the workhorse of oncology genomics, it is fundamentally designed to detect mutations, copy number variations, and structural rearrangements at the genomic level. Some biomarkers, however, manifest most clearly at the RNA or protein expression level, or involve gene fusions that DNA panels can struggle to characterize with adequate sensitivity. The study highlights that a meaningful subset of patients whose tumors harbor these alterations could receive an incomplete molecular picture if their clinical team depends solely on a DNA-centric workflow. For laboratories building out their oncology testing menus, this represents both a technical challenge and a clinical accountability question.

Clinical Context and the Case for Multimodal Profiling

The implications for clinical practice are considerable. Lung cancer treatment has become highly biomarker-driven, with approved therapies targeting specific fusions, splice variants, and expression-level alterations that require more than a standard DNA panel to reliably identify. If certain biomarkers are being systematically missed, some patients may be steered away from targeted therapies for which they are actually candidates, or may go through additional rounds of empirical treatment before the correct molecular driver is identified. This finding reinforces the argument that comprehensive genomic profiling in lung oncology should incorporate RNA sequencing or hybrid DNA-RNA approaches as a standard component rather than an optional add-on, a direction that several leading academic centers have already begun moving toward in their clinical protocols.

What's Next for Lung Cancer Genomic Testing Standards

The study arrives at a moment when the genomic testing landscape for lung cancer is already in flux, with recent FDA approvals expanding the scope of liquid biopsy panels and tumor-only sequencing assays entering the market. Professional societies and laboratory accreditation bodies will likely face renewed pressure to revisit their guidance on minimum testing requirements for lung malignancies. For test developers and clinical laboratory directors, the findings make a compelling case for investing in multi-analyte platforms capable of interrogating DNA, RNA, and potentially protein biomarkers within a single workflow.

As the oncology genomics field pushes toward ever more comprehensive tumor characterization, this research signals that the next competitive frontier for genetic testing providers will be defined not just by panel size, but by the breadth of molecular modalities a single assay can reliably interrogate.